Market Overview

Benzinga's Top #PreMarket Gainers

Related ACUR
MLV & Co Upgrades Acura Pharmaceuticals To Buy
Benzinga's Top Upgrades
Acura Pharmaceuticals' (ACUR) CEO Bob Jones on Q4 2014 Results - Earnings Call Transcript (Seeking Alpha)
Related GIVN
Benzinga's M&A Chatter for Monday December 9, 2013
Mid-Afternoon Market Update: Given Imaging Rallies on Acquisition; Markets Mixed

Given Imaging (NASDAQ: GIVN) surged 25.25% to $29.61 in the pre-market session after Covidien PLC (NYSE: COV) announced its plans to acquire Given Imaging for $30.00 per share in cash.

Acura Pharmaceuticals (NASDAQ: ACUR) soared 17.86% to $1.98 in the pre-market trading as the company announced results of meeting with the FDA.

Gilead Sciences (NASDAQ: GILD) shares jumped 3.39% to $76.50 in pre-market trading after the company reported positive data from interim Phase 2 results for GS-9973 in previously treated chronic lymphocytic leukemia.

Celgene (NASDAQ: CELG) shares gained 2.15% to $170.00 in the pre-market. Cantor lifted its price target on the stock from $171 to $186.

Posted-In: PreMarket GainersNews Pre-Market Outlook Markets Movers


Related Articles (ACUR + CELG)

Around the Web, We're Loving...

Get Benzinga's Newsletters

Benzinga PRO content